The Society of Surgical Oncology, inc.
The American Society of Breast Surgeons.
Annals of Surgical Oncology

Log in | Register

In vivo Toxicity and Bioavailability of Taxol® and a Paclitaxel/β-Cyclodextrin Formulation in a Rat Model During HIPEC

W. Bouquet PhD, W. Ceelen PhD, E. Adriaens PhD, A. Almeida Pharm, T. Quinten Pharm, F. De Vos PhD, P. Pattyn PhD, M. Peeters PhD, J. P. Remon PhD, C. Vervaet PhD
Gastrointestinal Oncology
Volume 17, Issue 9 / September , 2010

Abstract

Background

Peritoneal carcinomatosis (PC) remains a dreaded clinical syndrome and a common evolution of gastrointestinal and ovarian cancers. In recent years, hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has emerged as a promising strategy in the management of PC. In this study, a novel paclitaxel (Pac) formulation was investigated for its toxicity and bioavailability during HIPEC compared with Taxol®.

Materials and Methods

The maximum tolerated dose (MTD) after HIPEC of both formulations (Taxol® and Pac/RAME-β-CD) was determined. MTD was defined as the highest nonlethal dose with a reduction in body weight of ≤10% over 2 weeks. Blood parameters (red blood cell and white blood cell count, creatinine, ALT, and GGT) were evaluated over 20 days. Bioavailability of both Pac formulations after HIPEC was determined under normothermic (37°C) and hyperthermic (41°C) conditions for 90 min.

Results

Following HIPEC, both formulations had a similar MTD: 0.24 mg paclitaxel per ml. Red blood cell count decreased to a minimum after 10 days and was not fully recovered after 20 days for both formulations. White blood cell monitoring showed a significant increase in neutrocytes at day 10 and 15 for the Pac/RAME-β-CD formulation. Liver and kidney parameters did not change significantly. Bioavailability data of Pac/RAME-β-CD showed a 40-fold increase of the area under the curve (AUC) of plasma concentrations compared with Taxol®. Hyperthermia yielded no significant differences in bioavailability data.

Conclusion

These results showed that both formulations had a similar toxicity profile but differed significantly in bioavailability.

Add a comment



0 comment(s)

Special Announcement:             ASO IMPACT FACTOR RISES

The 2010 Impact Factor for Annals of Surgical Oncology has risen to 4.182, the third consecutive annual increase in the journal's impact ranking. The journal is now ranked 8 of 187 journals publishing in Thomson Reuters' (formerly ISI) subject category "Surgery," making it the top ranked oncology journal in surgery. The number of journal citations rose from 8,085 in 2008 to 11,090.

 

HIGHLIGHTED VIDEO OF THE MONTH

Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES) by R. A. Cahill MD, FRCS, S. Perretta MD, J. Leroy MD, B. Dallemagne MD, and J. Marescaux MD, FRCS, FACS.  Annals of Surgical Oncology. Volume 15, Number 10, DOI: 10.1245/s10434-008-9952-8